- Oral presentation
- Open Access
Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
Pediatric Rheumatologyvolume 9, Article number: O23 (2011)
More than 50% of JIA patients on Methotrexate (MTX) suffer from MTX-related gastrointestinal adverse effects – MTX intolerance (1). Nevertheless, the best approach to treat MTX intolerance is unknown.
To compare the effect of behavioural therapy or a switch to parenteral MTX with oral MTX on MTX intolerance.
45 JIA patients with MTX intolerance were randomised to receive oral MTX with anti-emetics (standard of care), parenteral MTX or oral MTX with behavioural therapy. Primary outcome was the occurrence of MTX intolerance, defined as ≥5 points on a validated MISS questionnaire, after a 3-month intervention period. Secondary outcome measures were: MTX intolerance after 6 and 12 months and the number of patients that discontinued MTX or switched to another treatment arm due to intolerance.
After 3 months MTX intolerance resolved in 6 (54.5%) patients on standard of care, 4 (57.1%) patients on parenteral MTX and 4 (36.4%) patients on behavioural therapy. Nine patients (30.0%) discontinued MTX or switched to another treatment arm due to MTX intolerance. Of remaining patients at 6 months, MTX intolerance resolved in 2 (50%), 4 (80%) and 4 (57.1%) patients, and at 12 months in 2 (66.7%), 4 (80%) and 3 (50%) patients in three treatment groups respectively. All treatment arms showed a marked decrease in MTX intolerance score on the MISS questionnaire from on average 15 points to 6 points after 3 months.
Behavioural therapy and parenteral MTX were not more effective than the standard of care in treating MTX intolerance. Instead, all treatments strongly diminished MTX intolerance, probably due to changes in cognitions and self-efficacy. Physicians should not discontinue MTX or switch to biologicals in case of MTX intolerance, but rather strengthen the patient’s self-efficacy to cope with MTX intolerance. We propose several strategies to this end.
Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP: High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011, Epub ahead of print